dm+d

Unassigned

New Medicines

Relapsing multiple sclerosis (MS)

Information

New molecular entity
Serono
EMD group

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Brutons Tyrosine Kinase inhibitor
The prevalence of MS recorded in the UK from 1990 to 2010 increased by about 2.4% per year, reaching 285.8 per 100 000 in women and 113.1 per 100 000 in men by 2010. Peak incidence occurs between ages 40 and 50 years [2]
Relapsing multiple sclerosis (MS)
Oral